BIOSCRIP, INC. (NASDAQ:BIOS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May 4, 2017, BioScrip, Inc. (the Company) issued a press
release reporting its 2017 first quarter financial results. A
copy of the press release is furnished with this Current Report
on Form 8-K as Exhibit 99.1 and is incorporated herein by
reference.
The press release includes certain non-GAAP financial measures as
described therein. As required by Regulation G, reconciliation
between any non-GAAP financial measures presented and the most
directly comparable GAAP financial measures is also provided.
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On May 2, 2017, the Company held its annual meeting of
stockholders, at which the following matters were voted upon:
(1) The nominees for election to the Companys Board of Directors
were elected, each for a term expiring at the Companys next
annual meeting, based on the following votes:
| Nominee | Votes For | Withheld | Broker Non-Votes | |||||||||
| Daniel E. Greenleaf | 93,066,500 | 325,167 | 26,226,131 | |||||||||
| Michael G. Bronfein | 92,799,910 | 591,757 | 26,226,131 | |||||||||
| David W. Golding | 92,944,290 | 447,377 | 26,226,131 | |||||||||
| Michael Goldstein | 92,551,229 | 840,438 | 26,226,131 | |||||||||
| Steven Neumann | 92,966,213 | 425,454 | 26,226,131 | |||||||||
| Tricia H. Nguyen | 92,962,210 | 429,457 | 26,226,131 | |||||||||
| R. Carter Pate | 92,974,955 | 416,712 | 26,226,131 | |||||||||
(2) The proposal to ratify the appointment of KPMG LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December 31, 2017 was approved based on the
following votes:
| FOR | AGAINST | ABSTAIN |
BROKER NON-VOTES |
|||||||||||
| 118,806,834 | 705,757 | 105,207 | ||||||||||||
(3) The proposal relating to the approval of the Companys Tax
Asset Protection Plan was approved based on the following votes:
| FOR | AGAINST | ABSTAIN |
BROKER NON-VOTES |
|||||||||||
| 86,866,701 | 6,467,694 | 57,272 | 26,226,131 | |||||||||||
(4) The proposal relating to the advisory vote on executive
compensation was approved based on the following votes:
| FOR | AGAINST | ABSTAIN |
BROKER NON-VOTES |
|||||||||||
| 92,242,985 | 796,760 | 351,922 | 26,226,131 | |||||||||||
(5) The proposal relating to the advisory vote on the frequency
of future advisory votes on the Companys executive compensation
was voted on as follows:
| ONE YEAR | Two Years | Three Years | ABSTAIN |
BROKER NON-VOTES |
||||||||||||||
| 88,034,769 | 307,154 | 4,747,481 | 302,263 | 26,226,131 | ||||||||||||||
In light of these voting results, the Company plans to hold
future advisory votes approving executive compensation annually
until the next required vote on the frequency of such advisory
votes, or until the Board of Directors of the Company otherwise
determines that a different frequency is in the best interests of
the Company and its stockholders.
Item 8.01. Other Events.
As previously announced, the Company will host a conference call
to discuss its 2017 first quarter financial results on May 4,
2017, at 9:00 a.m. Eastern Time. Interested parties may
participate in the conference call by dialing 888-372-9592 (U.S.)
or by accessing a link on the Companys website at
www.bioscrip.com 5-10 minutes prior to the start of the
call. A replay of the conference call will be available for two
weeks after the calls completion by dialing 855-859-2056 (U.S.)
and entering conference call ID number 8579499. An audio webcast
and archive will also be available for 30 days under the Investor
Relations section of the Companys website.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
See the Exhibit Index, which is hereby incorporated by reference.
As provided in General Instruction B.2 to Form 8-K, the
information furnished in Item 2.02 and in Exhibit 99.1 hereto, as
it relates to the Companys financial results for the quarter
ended March 31, 2017, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities under
that Section and shall not be deemed incorporated by reference
into any filing of the Company with the Securities and Exchange
Commission under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly provided by specific
reference in such filing.
About BIOSCRIP, INC. (NASDAQ:BIOS)
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment. BIOSCRIP, INC. (NASDAQ:BIOS) Recent Trading Information
BIOSCRIP, INC. (NASDAQ:BIOS) closed its last trading session up +0.12 at 1.65 with 1,645,402 shares trading hands.